Guidance ledger · Q4 FY26

Zydus Lifesciences Ltd ZYDUSLIFE

5 revisions on record · 0 lowered · 3 raised — the strikethrough is what management used to say

directional guidance only · shifted across quarters

Holding view → · latest concall · The pulse

→ narrowed FY26 US growth (Revlimid year) Q1 FY26 → Q4 FY26

~~Single digit growth (Q1FY26 guide)~~ → around 300 plus million base, single-digit FY27 too

“So we are around the 300 plus to 310 range. We had, as I said, maybe we'll have”

↑ raised FY26 EBITDA margin Q1 FY26 → Q4 FY26

~~better than 26% (Q1FY26)~~ → 31.2% FY26 full year actual, 33.7% Q4 actual

“profitability continued to improve with an EBITDA margin of 33.7%, which is an”

↑ raised FY27 EBITDA margin Q3 FY26 → Q4 FY26

~~23% plus despite no Revlimid (Q3FY26)~~ → in excess of 24%

“expecting margins in excess of 24%.”

→ narrowed India branded formulations vs IPM Q1 FY26 → Q4 FY26

~~outpace market (Q1FY26)~~ → outperform the market by 200-400 basis points versus the current IPM

“we will outperform the market by 200 -400 basis points versus”

↑ raised International markets growth Q3 FY26 → Q3 FY26

~~High teens to mid twenties (Q1FY26)~~ → 20% plus continuing for the near future / 40%+ FY26 actual

“Yeah, we see meaningfully 20% plus growth continuing for the near future.”

Method. Revisions come from management's own stated numbers, compared quarter over quarter across the covered concalls; each carries the verbatim quote. “No revisions” can also mean guidance too vague to pin down — see the posture chip above. Not investment advice.